Construction and Validation of a Nomogram Model for Predicting Diabetic Peripheral Neuropathy

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Dec 31

PMID 39736870

Authors

Hanying Liu

Qiao Liu

Mengdie Chen

Chaoyin Lu

Ping Feng

Affiliations

Soon will be listed here.

Abstract

Objective: Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes that can potentially escalate into ulceration, amputation and other severe consequences. The aim of this study was to construct and validate a predictive nomogram model for assessing the risk of DPN development among diabetic patients, thereby facilitating the early identification of high-risk DPN individuals and mitigating the incidence of severe outcomes.

Methods: 1185 patients were included in this study from June 2020 to June 2023. All patients underwent peripheral nerve function assessments, of which 801 were diagnosed with DPN. Patients were randomly divided into a training set (n =711) and a validation set (n = 474) with a ratio of 6:4. The least absolute shrinkage and selection operator (LASSO) logistic regression analysis was performed to identify independent risk factors and develop a simple nomogram. Subsequently, the discrimination and clinical value of the nomogram was extensively validated using receiver operating characteristic (ROC) curves, calibration curves and clinical decision curve analyses (DCA).

Results: Following LASSO regression analysis, a nomogram model for predicting the risk of DPN was eventually established based on 7 factors: age (OR = 1.02, 95%CI: 1.01 - 1.03), hip circumference (HC, OR = 0.94, 95%CI: 0.92 - 0.97), fasting plasma glucose (FPG, OR = 1.06, 95%CI: 1.01 - 1.11), fasting C-peptide (FCP, OR = 0.66, 95%CI: 0.56 - 0.77), 2 hour postprandial C-peptide (PCP, OR = 0.78, 95%CI: 0.72 - 0.84), albumin (ALB, OR = 0.90, 95%CI: 0.87 - 0.94) and blood urea nitrogen (BUN, OR = 1.08, 95%CI: 1.01 - 1.17). The areas under the curves (AUC) of the nomogram were 0.703 (95% CI 0.664-0.743) and 0.704 (95% CI 0.652-0.756) in the training and validation sets, respectively. The Hosmer-Lemeshow test and calibration curves revealed high consistency between the predicted and actual results of the nomogram. DCA demonstrated that the nomogram was valuable in clinical practice.

Conclusions: The DPN nomogram prediction model, containing 7 significant variables, has exhibited excellent performance. Its generalization to clinical practice could potentially help in the early detection and prompt intervention for high-risk DPN patients.

References

Katsiki N, Anagnostis P, Kotsa K, Goulis D, Mikhailidis D . Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Curr Pharm Des. 2019; 25(18):2051-2059. DOI: 10.2174/1381612825666190708192134. View

Cheng Y, Cao W, Zhang J, Wang J, Liu X, Wu Q . Determinants of Diabetic Peripheral Neuropathy and Their Clinical Significance: A Retrospective Cohort Study. Front Endocrinol (Lausanne). 2022; 13:934020. PMC: 9360478. DOI: 10.3389/fendo.2022.934020. View

Porter S, Massaro J, Hoffmann U, Vasan R, ODonnel C, Fox C . Abdominal subcutaneous adipose tissue: a protective fat depot?. Diabetes Care. 2009; 32(6):1068-75. PMC: 2681034. DOI: 10.2337/dc08-2280. View

Kaur M, Misra S, Swarnkar P, Patel P, Kurmi B, Gupta G . Understanding the role of hyperglycemia and the molecular mechanism associated with diabetic neuropathy and possible therapeutic strategies. Biochem Pharmacol. 2023; 215:115723. DOI: 10.1016/j.bcp.2023.115723. View

Fang H, Berg E, Cheng X, Shen W . How to best assess abdominal obesity. Curr Opin Clin Nutr Metab Care. 2018; 21(5):360-365. PMC: 6299450. DOI: 10.1097/MCO.0000000000000485. View

Riley R, Ensor J, Snell K, Harrell Jr F, Martin G, Reitsma J . Calculating the sample size required for developing a clinical prediction model. BMJ. 2020; 368:m441. DOI: 10.1136/bmj.m441. View

Sloan G, Selvarajah D, Tesfaye S . Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021; 17(7):400-420. DOI: 10.1038/s41574-021-00496-z. View

Xu L, Lin X, Guan M, Liu Y . Correlation Between Different Stages of Diabetic Nephropathy and Neuropathy in Patients with T2DM: A Cross-Sectional Controlled Study. Diabetes Ther. 2018; 9(6):2335-2346. PMC: 6250626. DOI: 10.1007/s13300-018-0519-9. View

Wu B, Niu Z, Hu F . Study on Risk Factors of Peripheral Neuropathy in Type 2 Diabetes Mellitus and Establishment of Prediction Model. Diabetes Metab J. 2021; 45(4):526-538. PMC: 8369209. DOI: 10.4093/dmj.2020.0100. View

10.

Shabeeb D, Najafi M, Hasanzadeh G, Hadian M, Musa A, Shirazi A . Electrophysiological measurements of diabetic peripheral neuropathy: A systematic review. Diabetes Metab Syndr. 2018; 12(4):591-600. DOI: 10.1016/j.dsx.2018.03.026. View

11.

Selvarajah D, Kar D, Khunti K, Davies M, Scott A, Walker J . Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019; 7(12):938-948. DOI: 10.1016/S2213-8587(19)30081-6. View

12.

Grisold A, Callaghan B, Feldman E . Mediators of diabetic neuropathy: is hyperglycemia the only culprit?. Curr Opin Endocrinol Diabetes Obes. 2017; 24(2):103-111. PMC: 5831542. DOI: 10.1097/MED.0000000000000320. View

13.

Yang J, Jiang S . Development and validation of a model that predicts the risk of diabetic retinopathy in type 2 diabetes mellitus patients. Acta Diabetol. 2022; 60(1):43-51. DOI: 10.1007/s00592-022-01973-1. View

14.

Yan P, Tang Q, Wu Y, Wan Q, Zhang Z, Xu Y . Serum albumin was negatively associated with diabetic peripheral neuropathy in Chinese population: a cross-sectional study. Diabetol Metab Syndr. 2021; 13(1):100. PMC: 8444578. DOI: 10.1186/s13098-021-00718-4. View

15.

Dyck P, Carter R, Litchy W . Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve. 2011; 44(3):340-5. PMC: 3193597. DOI: 10.1002/mus.22074. View

16.

Yang J, Jiang S . Development and Validation of a Model That Predicts the Risk of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study. Int J Gen Med. 2022; 15:5089-5101. PMC: 9130557. DOI: 10.2147/IJGM.S363474. View

17.

Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X . Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Front Endocrinol (Lausanne). 2024; 14:1265372. PMC: 10803883. DOI: 10.3389/fendo.2023.1265372. View

18.

Belayev L, Liu Y, Zhao W, Busto R, Ginsberg M . Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001; 32(2):553-60. DOI: 10.1161/01.str.32.2.553. View

19.

Wang W, Ji Q, Ran X, Li C, Kuang H, Yu X . Prevalence and risk factors of diabetic peripheral neuropathy: A population-based cross-sectional study in China. Diabetes Metab Res Rev. 2023; 39(8):e3702. DOI: 10.1002/dmrr.3702. View

20.

Zhu Y, Cai X, Liu Y, Hu M, Zhou L, Liu W . Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population. Sci Rep. 2019; 9(1):12086. PMC: 6700065. DOI: 10.1038/s41598-019-48486-6. View